Cytokines and their receptors as biomarkers of systemic lupus erythematosus

References

• D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet369, 587–596 (2007).
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity39, 705–709 (2006).
   PubMed Web of Science ®Google Scholar
• Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum.42, 46–50 (1999).
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum.54, 2550–2557 (2006).
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)82, 299–308 (2003).
   PubMed Web of Science ®Google Scholar
• Merrill JT, Buyon JP. The role of biomarkers in the assessment of lupus. Best Pract. Res. Clin. Rheumatol.19, 709–726 (2005).
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr. Opin. Rheumatol.17, 543–549 (2005).
   PubMed Web of Science ®Google Scholar
• Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum.50, 2415–2422 (2004).
   PubMed Web of Science ®Google Scholar
• Mittleman BB. Biomarkers for systemic lupus erythematosus: has the right time finally arrived? Arthritis Res. Ther.6, 223–224 (2004).
   Google Scholar
• Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum.50, 2048–2065 (2004).
   PubMed Web of Science ®Google Scholar
• Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum.50, 1709–1720 (2004).
   PubMed Web of Science ®Google Scholar
• Kirou KA, Salmon JE, Crow MK. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am.32, 103–119, ix (2006).
   PubMed Web of Science ®Google Scholar
• Doria A, Ghirardello A, Iaccarino L et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum.51, 989–995 (2004).
   PubMed Web of Science ®Google Scholar
• Lit LC, Wong CK, Li EK, Tam LS, Lam CW, Lo YM. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J. Rheumatol.34, 89–96 (2007).
   PubMed Web of Science ®Google Scholar
• Gomez D, Correa PA, Gomez LM, Cadena J, Molina JF, Anaya JM. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor α protective? Semin. Arthritis Rheum.33, 404–413 (2004).
   PubMed Web of Science ®Google Scholar
• Gladman DD. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol.29, 288–291 (2002).
   PubMed Web of Science ®Google Scholar
• Kallenberg CG, Stegeman CA, Bootsma H, Bijl M, Limburg PC. Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful? Lupus15, 397–402 (2006).
   PubMedGoogle Scholar
• Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus13, 298–303 (2004).
   Google Scholar
• Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol.30, 485–492 (2003).
   Google Scholar
• Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J. Rheumatol.30, 2133–2139 (2003).
   PubMed Web of Science ®Google Scholar
• Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin. Exp. Immunol.138, 348–356 (2004).
   PubMed Web of Science ®Google Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J. Immunol.172, 3983–3988 (2004).
   PubMed Web of Science ®Google Scholar
• Chan RW, Lai FM, Li EK et al. Intrarenal cytokine gene expression in lupus nephritis. Ann. Rheum. Dis.66, 886–892 (2007).
   PubMedGoogle Scholar
• Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis.65, 209–215 (2006).
   PubMed Web of Science ®Google Scholar
• Chun HY, Chung JW, Kim HA et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol.27, 461–466 (2007).
   PubMed Web of Science ®Google Scholar
• Daza L, Lavalle C, Duarte C, Huerta R, Moreno J. Lack of association between hyperprolactinemia and soluble IL-2 receptor levels in systemic lupus erythematosus. Lupus12, 107–111 (2003).
   Google Scholar
• Singh RR. IL-4 and many roads to lupuslike autoimmunity. Clin. Immunol.108, 73–79 (2003).
   PubMedGoogle Scholar
• Soltesz P, Aleksza M, Antal-Szalmas P, Lakos G, Szegedi G, Kiss E. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity35, 51–56 (2002).
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology. Annu. Rev. Immunol.23, 1–21 (2005).
   PubMed Web of Science ®Google Scholar
• Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus13, 339–343 (2004).
   PubMed Web of Science ®Google Scholar
• Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J. Biol. Chem.279, 16121–16127 (2004).
   Google Scholar
• Sabry A, Sheashaa H, El-Husseini A et al. Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine35, 148–153 (2006).
   PubMed Web of Science ®Google Scholar
• Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus15, 268–275 (2006).
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol.33, 539–545 (2006).
   PubMed Web of Science ®Google Scholar
• Suh CH, Chun HY, Ye YM, Park HS. Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin. Immunol.119, 291–296 (2006).
   PubMed Web of Science ®Google Scholar
• Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis.64, 849–853 (2005).
   PubMed Web of Science ®Google Scholar
• Sabry A, Elbasyouni SR, Sheashaa HA et al. Correlation between levels of TNF-α and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int. Urol. Nephrol.38, 731–737 (2006).
   Google Scholar
• Katsumata Y, Harigai M, Kawaguchi Y et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-α, IgG index, and Q-albumin. J. Rheumatol.34, 2010–2017 (2007).
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol.22, 929–979 (2004).
   PubMed Web of Science ®Google Scholar
• Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol.23, 89–96 (2002).
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y. The role of interleukin-10 in systemic lupus erythematosus. J. Autoimmun.20, 287–289 (2003).
   PubMed Web of Science ®Google Scholar
• Beebe AM, Cua DJ, de Waal Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev.13, 403–412 (2002).
   PubMed Web of Science ®Google Scholar
• Enghard P, Langnickel D, Riemekasten G. T cell cytokine imbalance towards production of IFN-γ and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand. J. Rheumatol.35, 209–216 (2006).
   PubMed Web of Science ®Google Scholar
• Grondal G, Traustadottir KH, Kristjansdottir H et al. Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus11, 435–442 (2002).
   PubMed Web of Science ®Google Scholar
• Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis.62, 37–42 (2003).
   PubMed Web of Science ®Google Scholar
• Baraczka K, Nekam K, Pozsonyi T, Szuts I, Ormos G. Investigation of cytokine (tumor necrosis factor-α, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur. J. Neurol.11, 37–42 (2004).
   PubMedGoogle Scholar
• Yin Z, Bahtiyar G, Zhang N et al. IL-10 regulates murine lupus. J. Immunol.169, 2148–2155 (2002).
   PubMed Web of Science ®Google Scholar
• Tejde A, Mathsson L, Ekdahl KN, Nilsson B, Ronnelid J. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system. Clin. Exp. Immunol.137, 521–528 (2004).
   Google Scholar
• Lauwerys BR, Van Snick J, Houssiau FA. Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus11, 384–387 (2002).
   PubMed Web of Science ®Google Scholar
• Tso TK, Huang WN, Huang HY, Chang CK. Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus. Lupus15, 207–212 (2006).
   PubMed Web of Science ®Google Scholar
• Spadaro A, Scrivo R, Bombardieri M et al. Relationship of interleukin-12 and interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin. Rheumatol.22, 107–111 (2003).
   Google Scholar
• Mosaad YM, Metwally SS, Auf FA et al. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. Egypt. J. Immunol.10, 19–26 (2003).
   Google Scholar
• Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepien H. Proinflammatory interferon-γ – inducing monokines (interleukin-12, interleukin-18, interleukin-15) – serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw.13, 364–368 (2002).
   Google Scholar
• Baranda L, de la Fuente H, Layseca-Espinosa E et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford)44, 1507–1513 (2005).
   Web of Science ®Google Scholar
• Glass WG, Sarisky RT, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J. Interferon Cytokine Res.26, 511–520 (2006).
   PubMedGoogle Scholar
• Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus11, 181–185 (2002).
   Google Scholar
• Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev.4, 542–548 (2005).
   PubMed Web of Science ®Google Scholar
• Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA100, 14181–14186 (2003).
   PubMed Web of Science ®Google Scholar
• Tso TK, Huang WN, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford)45, 1148–1153 (2006).
   PubMed Web of Science ®Google Scholar
• Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin. Rheumatol.23, 225–229 (2004).
   PubMed Web of Science ®Google Scholar
• Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol.130, 345–351 (2002).
   PubMed Web of Science ®Google Scholar
• Amerio P, Frezzolini A, Abeni D et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin. Exp. Rheumatol.20, 535–538 (2002).
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Suriano A, Dietzmann K, Lin J, Goldman D, Petri MA. The TNFα locus is altered in monocytes from patients with systemic lupus erythematosus. Clin. Immunol.123, 74–81 (2007).
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum.50, 3161–3169 (2004).
   PubMed Web of Science ®Google Scholar
• Aringer M, Feierl E, Steiner G et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus11, 102–108 (2002).
   PubMed Web of Science ®Google Scholar
• Sjowall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T. Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus. J. Autoimmun.22, 315–323 (2004).
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol.17, 518–522 (2005).
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-α and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin. Biochem.38, 134–141 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Mutairi S, Al-Awadhi A, Raghupathy R et al. Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile. Rheumatol. Int.27, 621–630 (2007).
   Google Scholar
• Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus14, 13–18 (2005).
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA. Interferon-α in systemic lupus erythematosus. Curr. Opin. Rheumatol.16, 541–547 (2004).
   PubMed Web of Science ®Google Scholar
• Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol.16, 801–807 (2004).
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res. Ther.5, 68–75 (2003).
   PubMed Web of Science ®Google Scholar
• Dall’era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis.64, 1692–1697 (2005).
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science16, 294(5546) 1540–1543 (2001).
   Google Scholar
• Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus9(9), 664–671 (2000).
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA100, 2610–2615 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med.197, 711–723 (2003).
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum.50, 3958–3967 (2004).
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-a pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum.52, 1491–1503 (2005).
   PubMed Web of Science ®Google Scholar
• Jin O, Sun LY, Zhou KX et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin. Rheumatol.24, 107–110 (2005).
   PubMed Web of Science ®Google Scholar
• Utz PJ. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. Lupus13, 304–311 (2004).
   Google Scholar